|
|
Volumn 29, Issue 6 Suppl 16, 2002, Pages 10-14
|
|
Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
BEVACIZUMAB;
ENDOTHELIAL CELL GROWTH FACTOR;
LYMPHOKINE;
MONOCLONAL ANTIBODY;
SIGNAL PEPTIDE;
VASCULOTROPIN;
VASCULOTROPIN A;
VASCULOTROPIN RECEPTOR;
ANGIOGENESIS;
ANIMAL;
CAPILLARY PERMEABILITY;
CLINICAL TRIAL;
DRUG ANTAGONISM;
HUMAN;
NEOPLASM;
NEOVASCULARIZATION (PATHOLOGY);
PATHOPHYSIOLOGY;
PHYSIOLOGY;
RETINA MACULA DEGENERATION;
REVIEW;
SIGNAL TRANSDUCTION;
VASCULARIZATION;
ANGIOGENESIS INHIBITORS;
ANIMALS;
ANTIBODIES, MONOCLONAL;
CAPILLARY PERMEABILITY;
CLINICAL TRIALS;
ENDOTHELIAL GROWTH FACTORS;
HUMANS;
INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS;
LYMPHOKINES;
MACULAR DEGENERATION;
NEOPLASMS;
NEOVASCULARIZATION, PATHOLOGIC;
NEOVASCULARIZATION, PHYSIOLOGIC;
RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;
SIGNAL TRANSDUCTION;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
VASCULAR ENDOTHELIAL GROWTH FACTORS;
MLCS;
MLOWN;
|
|
EID: 0036985699
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: 10.1016/s0093-7754(02)70064-x Document Type: Review |
|
Times cited : (624)
|
|
References (34)
|
